What do people on the left say about Prescription Drug Pricing?

Americans pay substantially more for the same drugs than patients in comparable wealthy countries. Medicare's first negotiated prices took effect in January 2026 at discounts of 38 to 79 percent off list. Ten drugs alone accounted for roughly 20 percent of all Part D spending, so a narrow program reaches broad costs.

What do people on the right say about Prescription Drug Pricing?

Price controls reduce the expected return on risky research, and analysts estimate a measurable if modest loss of future drugs. Government price setting substitutes an administrative judgment for market signals about what a treatment is worth. Middlemen capture a large share of the gap between list and net prices, so rebate reform may target the real problem more precisely.

5050

Fifty Fifty Politics

Choose a topic. Gain insight. Stay informed on the views from the left to the right.

Prescription Drug Pricing

Whether the government should set or negotiate prices for prescription drugs, and how that affects costs today against innovation tomorrow.

Left-leaning view

Americans pay substantially more for the same drugs than patients in comparable wealthy countries.
International comparisons consistently show U.S. list prices well above those in other high-income countries for identical products, largely because most peer nations negotiate or reference-price centrally while U.S. Medicare was long prohibited from doing so. Supporters argue this is a policy choice rather than an inevitability. Critics note that comparisons using list rather than net prices overstate the gap, since U.S. rebates are large and confidential, and that other countries often get later access to new drugs in exchange for lower prices.
Medicare's first negotiated prices took effect in January 2026 at discounts of 38 to 79 percent off list.
Negotiated prices for the first ten selected drugs took effect on January 1, 2026, with maximum fair prices set between 38 and 79 percent below 2023 list prices. Eliquis, for example, moved from a list price near $592 a month to roughly $231. The Centers for Medicare and Medicaid Services projected about $6 billion in program savings in the first year plus roughly $1.5 billion in reduced out-of-pocket costs. Actual savings depend on plan design, since what a patient pays still varies by tier and copay structure.
Ten drugs alone accounted for roughly 20 percent of all Part D spending, so a narrow program reaches broad costs.
The ten drugs in the first round accounted for about $50.5 billion in Part D spending in 2023, close to 20 percent of total gross Part D drug costs. Supporters argue this concentration is the point: because spending clusters heavily in a small number of high-cost products, a program covering relatively few drugs can still reach a large share of the bill. The second round covers fifteen more drugs for 2027, representing roughly $42.5 billion in spending across about 5.7 million beneficiaries. Whether that expansion pace is aggressive or cautious is itself contested.
High out-of-pocket costs cause patients to ration or abandon prescriptions, worsening outcomes and downstream spending.
Surveys have repeatedly found patients skipping doses, splitting pills, or leaving prescriptions unfilled because of cost, and cost-related nonadherence is associated with worse outcomes and higher spending on hospitalization later. The Inflation Reduction Act capped Part D out-of-pocket costs at $2,000 a year beginning in January 2026, replacing a structure with no ceiling. Supporters argue predictability matters as much as the average price. Critics note the cap shifts costs to premiums and taxpayers rather than eliminating them.
Much foundational research is publicly funded, so taxpayers arguably pay twice under current pricing.
The National Institutes of Health funds a large share of the basic science that underlies later commercial development, and studies tracing drug approvals back to publicly funded research have found federal support behind a substantial portion of new molecular entities. Advocates argue that taxpayers therefore fund discovery and then pay premium prices for the result. Industry responds that basic science and drug development are different undertakings, and that the overwhelming majority of the cost and risk sits in clinical trials that the private sector bears. Estimates of the public share vary widely depending on whether upstream basic science or direct development funding is counted.

Right-leaning view

Price controls reduce the expected return on risky research, and analysts estimate a measurable if modest loss of future drugs.
The central tradeoff is between prices today and drugs tomorrow. One analysis of the first negotiation round estimated the eleven manufacturers involved would collectively develop about 0.62 fewer novel drugs as a result, while also concluding those firms were well positioned to absorb the effect through other revenue or cost cutting. Supporters of negotiation read that as a small price for billions in savings. Opponents argue the estimate covers only the first ten drugs, and that effects compound as the program expands to twenty additional drugs annually.
Government price setting substitutes an administrative judgment for market signals about what a treatment is worth.
Critics argue that a negotiated maximum fair price is ultimately an administrative determination of what a therapy is worth, made under statutory formulas and time pressure rather than by the interaction of many buyers and sellers. They contend such judgments handle novel or small-population treatments poorly. Defenders respond that Medicare is a monopsony buyer whose prior inability to negotiate was itself an artificial market distortion, and that every other large purchaser in the system already negotiates. The statute does list factors the agency must weigh, though critics argue those factors still leave wide discretion.
Middlemen capture a large share of the gap between list and net prices, so rebate reform may target the real problem more precisely.
A substantial share of the difference between list and net prices flows to pharmacy benefit managers, wholesalers, and pharmacies rather than to manufacturers. Because rebates are typically confidential and often calculated as a percentage of list, some argue the structure creates an incentive to raise list prices. Reformers on this side favor rebate transparency or delinking compensation from list price as a more targeted fix. Critics respond that PBM reform and negotiation are complements rather than alternatives.
Negotiated savings are modest against total Medicare drug spending, raising doubts about scale relative to the tradeoff.
Total Medicare drug spending exceeds $200 billion annually, so first-year savings of roughly $6 billion represent a small fraction of the whole. Skeptics use this to argue that the program's disruption to research incentives is poorly matched to its fiscal return. Supporters counter that the program was deliberately phased, that year two is estimated near $12 billion, and that measuring a scaling program by its smallest year understates it. The honest version of the dispute is about the right time horizon for judging a program still in its early rounds.
Lower U.S. prices could reduce the global research subsidy America currently provides, shifting costs rather than eliminating them.
Because the United States pays more than other wealthy countries for the same products, U.S. revenue effectively funds a disproportionate share of global pharmaceutical research. Critics of negotiation argue that lowering American prices without other countries raising theirs reduces total research funding rather than redistributing it fairly. Supporters respond that this makes the case for pressuring peer nations to pay more, not for American patients to keep absorbing the difference indefinitely.

Sources

Wikipedia: Foreign military aid to Ukraine during the Russo-Ukrainian War Council on Foreign Relations AllSides: Compare Left/Center/Right Coverage Brookings Institution: Foreign Policy

Discussion

0/1000

5050Politics.com

With any inquiries, please reach out to 5050politics@gmail.com.